Clinical trials: Demyelinating Disorder
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
The primary objective of the study is to further evaluate the long-term safety and tolerability profiles of BG00002 (natalizumab) in Japanese participants with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01416155
- Testing
- natalizumab
- Where
- 22 sites in Japan
- Volunteers
- 97 people
- Sponsor
- Biogen
Guillain-Barre Syndrome
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
This is a Phase 3, prospective, multicenter, placebo controlled, double blind, randomized study to investigate the efficacy and safety of eculizumab in participants with severe GBS, defined using the Hughes Functional Grade (FG)…
- Trial name
- NCT04752566
- Testing
- Eculizumab
- Where
- 22 sites in Japan
- Volunteers
- 57 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Sclerosis
Self-Directed Positive Psychology Intervention for Newly Diagnosed Multiple Sclerosis
The goal of this clinical trial is to learn whether positive psychology (PP) exercises such as writing a letter of gratitude or remembering a past success can help individuals with newly diagnosed multiple sclerosis (MS) to feel…
- Trial name
- NCT06891937
- Testing
- Positive psychology
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS…
- Trial name
- MUSETTE (NCT04544436)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 864 people
- Sponsor
- Hoffmann-La Roche
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Progressive Multiple Sclerosis
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS).
- Trial name
- NCT03423121
- Testing
- Tauroursodeoxycholic Acid
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Johns Hopkins University
Relapsing Remitting Multiple Sclerosis
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
The study is designed to assess the efficacy of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in subjects with RRMS, as measured by the number of confirmed relapses during the 12…
- Trial name
- GALA (NCT01067521)
- Testing
- Glatiramer acetate (GA)
- Where
- 176 sites in United States, Bulgaria and 15 more
- Volunteers
- 1,404 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
The main aim was to study in the real world setting the effectiveness of Cladribine tablets in terms of Annualized Relapse Rate (ARR) and disability progression, in participants who switched from a first line Disease Modifying…
- Trial name
- NCT04934800
- Testing
- Cladribine
- Where
- 61 sites in Austria, Greece and 5 more
- Volunteers
- 256 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo.
- Trial name
- NCT01625182
- Testing
- Fingolimod
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis (MS). Although abatacept is an investigational medication for MS, it is not a new drug.
- Trial name
- ACCLAIM (NCT01116427)
- Testing
- abatacept
- Where
- 21 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsing Remitting Multiple Sclerosis
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg).
- Trial name
- SURPASS (NCT01058005)
- Testing
- BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 84 people
- Sponsor
- Biogen
Multiple Sclerosis
Testosterone Treatment for Multiple Sclerosis
Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel.
- Trial name
- NCT00405353
- Testing
- Androgel 10 grams of gel containing 100 mg of testosterone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
This study will test the tolerability and preliminary efficacy of transcranial direct current stimulation (tDCS) combined with a cognitive training program, remotely-delivered using a telemedicine protocol in 60 adults with…
- Trial name
- NCT02746705
- Testing
- Transcranial Direct Current Stimulation (tDCS), Cognitive Training Program
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Memory Disorders, Multiple Sclerosis
Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)
The purpose of this crossover trial is to investigate whether atomoxetine (versus placebo) improves memory function in persons with memory deficits due to multiple sclerosis.
- Trial name
- NCT03091400
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched…
- Trial name
- SUSTAIN (NCT02881567)
- Testing
- Daclizumab
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Biogen
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS…
- Trial name
- GAVOTTE (NCT04548999)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 147 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis [MS].
- Trial name
- TENERE (NCT00883337)
- Testing
- Interferon β-1a, Teriflunomide
- Where
- 54 sites in Belgium, Canada and 11 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Relapsing Multiple Sclerosis (RMS)
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to…
- Trial name
- NCT04878211
- Testing
- Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Tele-Exercise and Multiple Sclerosis
The purpose of this study is to compare the effects of two delivery models of an evidence-based complementary alternative medicine (CAM) program that combines neurorehabilitative (functional) exercise, yoga, and Pilates for…
- Trial name
- TEAMS (NCT03117881)
- Testing
- DirectCAM, TeleCAM, rDirectCAM
- Where
- 40 sites in United States
- Volunteers
- 911 people
- Sponsor
- University of Alabama at Birmingham
Relapsing-remitting Multiple Sclerosis (RRMS)
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
- Trial name
- ASSESS (NCT01633112)
- Testing
- fingolimod, glatiramer acetate
- Where
- 130 sites in United States, Argentina and 5 more
- Volunteers
- 1,064 people
- Sponsor
- Novartis Pharmaceuticals